News • miR-634 vs. OSCC

Anti-cancer "dream cream" to shrink oral tumors

Modern medicine offers “peel and stick” solutions like nicotine or contraceptive patches to put right on the skin without needing to visit a doctor for an injection or procedure. Now, researchers have found that applying a topical ointment containing anti-tumor factor can increase the effectiveness of cancer treatment.

Cream applied to finger (symbolic photo)

Image source: Adobe Stock/triocean

In a study published in Molecular Therapy Oncolytics, researchers from Tokyo Medical and Dental University (TMDU) reveal that treating oral cancer cells with miR-634, a microRNA that targets pro-tumor factors, can increase the effectiveness of treatment with cisplatin. 

Over 90% of cases of oral cancer are a type of cancer called oral squamous cell carcinoma (OSCC). While OSCC can be treated with chemotherapy and radiation, many patients develop resistance to cisplatin, the main drug used to treat it. “We recently found that miR-634 counteracts some cell-protective processes, such as anti-apoptotic signaling and antioxidant scavenging, that are activated in cancer cells that are resistant to cisplatin,” says Phuong Xuan Tran, lead author on the study. “This suggests that increasing the amount of this small molecule in cells could increase their sensitivity to this drug.”

To test whether miR-634 can help increase tumor sensitivity to cisplatin, the researchers treated two different OSCC cell lines with both the miRNA and the drug and looked at how many of the cells survived. “The results were very clear,” states Johji Inazawa, senior author of the study. “Treatment with miR-634 effectively increased cisplatin-induced cytotoxicity and overcame cisplatin resistance in OSCC cells, resulting in increased tumor cell killing.”

Graphical abstract of the research findings

Image source: Tran et al, Molecular Therapy Oncolytics 2022 (CC BY-NC-ND 4.0)

To confirm these results, the researchers then tested the treatment combination in mice with experimental tumors. When the mice were injected with cisplatin and an miR-634 ointment was applied to the tumors, the tumors shrank rapidly. “Our findings suggest that miR-634-mediated repression of pro-tumor factors can effectively increase the sensitivity of OSCC to existing chemotherapeutic options such as cisplatin,” says Tran. 

Taken together, the results from this study suggest that miR-634 ointment could be useful for enhancing the effects of chemotherapy in patients with advanced OSCC. Given that the synergistic effects of miR-634 and cisplatin were also seen in esophageal squamous cell carcinoma, bladder cancer, and ovarian cancer cell lines, this treatment combination may also be effective across a variety of cancer types. 

In OSCC, the expression of miR-634 target genes is upregulated and contributes to the resistance to cisplatin (CDDP). miR-634 introduction into OSCC cells overcomes CDDP resistance by simultaneously targeting multiple genes associated with cytoprotective processes. In this study, cIAP1 wasnewly identified, which plays a central role in the anti-apoptotic process, as a target of miR-634.


Read all latest stories

Related articles


News • Atypical teratoid/rhabdoid tumours

Understanding the development of AT/RT brain cancer in children

Unlike most tumours, atypical teratoid/rhabdoid (AT/RT) tumours develop very quickly. Now, researchers explored the mechanisms of these aggressive brain tumours that mainly affect young children.


News • Voice box cancer treatment

Laryngeal cancer: AI software to better predict outcomes

Experts at Newcastle University have discovered artificial intelligence can be used to analyse medical imaging from CT scans, which is aimed at predicting survival in patients with laryngeal cancer.


News • Research on biomechanics

Tumour 'softness' can drive aggressiveness of breast cancer

Researchers have discovered how the mechanical properties of tumours - their softness, for example - can prime cancer cells to better survive their spread to other organs.

Related products

Subscribe to Newsletter